30% off. Use code SUMMERSALE30 at checkout for 30% off for 12 months on Plus, Pro and Premium subscriptions. Subscribe now
United States Biotechnology & Medical Research

Rigel Pharmaceuticals Inc (RIGL)

Track

Over the last 90 days, Rigel Pharmaceuticals Inc. has seen two insider transactions, both sales totaling $145,850. Notably, Director Kamil Ali-Jackson sold shares on May 26, 2026. The company's stock has increased by 24.2% in the past 90 days. The last earnings report on May 5, 2026, showed an EPS miss of 49.4%.
Stock chart
Ticker: RIGL Exchange: NSM
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


Subscribe to get access to the transaction volume chart and in-chart transaction details
• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Activity signal Earnings
Top insiders
Trades
Ali-Jackson Kamil
2 sales — total 145,850 USD
Planned sale 26 May 2026
Value US$2,022,599.45 | Price 430.09 | Shares 10,440
Proposed sale 26 May 2026
Value US$1,962,193.25 | Price 227.14 | Shares 96,367
Sale 20 Feb 2026
Value US$4,664,551.81 | Price 120.94 | Shares 10,019
Proposed sale 20 Feb 2026
Value US$4,424,639.31 | Price 231.54 | Shares 69,996
Sale 5 Feb 2025
Value US$39,379.10 | Price 21.93 | Shares 1,796
Proposed sale 5 Feb 2025
Value US$39,379.09 | Price 21.93 | Shares 1,796
Sale 5 Feb 2025
Value US$29,358.91 | Price 21.93 | Shares 1,339
Proposed sale 5 Feb 2025
Value US$29,358.91 | Price 21.93 | Shares 1,339
Sale 5 Feb 2025
Value US$96,474.40 | Price 21.93 | Shares 4,400
Proposed sale 5 Feb 2025
Value US$96,474.40 | Price 21.93 | Shares 4,400
Sale 5 Feb 2025
Value US$38,019.68 | Price 21.93 | Shares 1,734
Proposed sale 5 Feb 2025
Value US$38,019.69 | Price 21.93 | Shares 1,734
Sale 4 Feb 2025
Value US$44,457.12 | Price 20.92 | Shares 2,125
Proposed sale 4 Feb 2025
Value US$44,457.76 | Price 20.92 | Shares 2,125
Sale 4 Feb 2025
Value US$30,293.61 | Price 20.92 | Shares 1,448
Proposed sale 4 Feb 2025
Value US$30,294.04 | Price 20.92 | Shares 1,448
Sale 4 Feb 2025
Value US$103,600.79 | Price 20.92 | Shares 4,952
Proposed sale 4 Feb 2025
Value US$103,602.27 | Price 20.92 | Shares 4,952
Sale 4 Feb 2025
Value US$42,595.16 | Price 20.92 | Shares 2,036
Proposed sale 4 Feb 2025
Value US$42,595.77 | Price 20.92 | Shares 2,036
Proposed sale 24 Jan 2025
Value US$110,677.66 | Price 22.14 | Shares 4,999
Sale 5 Feb 2024
Value US$34,821.30 | Price 1.14 | Shares 30,545
Sale 5 Feb 2024
Value US$8,010.78 | Price 1.14 | Shares 7,027
Sale 5 Feb 2024
Value US$10,166.52 | Price 1.14 | Shares 8,918
Sale 2 Feb 2024
Value US$25,261.07 | Price 1.13 | Shares 22,349
Sale 2 Feb 2024
Value US$6,326.89 | Price 1.13 | Shares 5,601
Sale 2 Feb 2024
Value US$6,329.13 | Price 1.13 | Shares 5,601
Sale 6 Feb 2023
Value US$35,595.00 | Price 1.75 | Shares 20,340
Sale 2 Feb 2023
Value US$8,946.28 | Price 1.66 | Shares 5,389
Sale 2 Feb 2023
Value US$8,945.16 | Price 1.66 | Shares 5,388
Sale 2 Feb 2023
Value US$8,946.28 | Price 1.66 | Shares 5,389
Buy 9 Jun 2022
Value US$688,400.00 | Price 0.69 | Shares 1,000,000
Buy 22 May 2019
Value US$6,971.00 | Price 2.13 | Shares 3,274
Buy 22 May 2019
Value US$99,573.11 | Price 2.13 | Shares 46,726
Planned sale 12 Oct 2018
Value US$31,200.00 | Price 3.12 | Shares 10,000
Planned sale 17 Sep 2018
Value US$131,250.00 | Price 3.50 | Shares 37,500
Planned sale 17 Sep 2018
Value US$404,250.00 | Price 3.50 | Shares 115,500
Buy 11 Sep 2018
Value US$161,340.00 | Price 3.23 | Shares 50,000
Buy 10 Sep 2018
Value US$164,210.00 | Price 3.28 | Shares 50,000
Planned sale 4 Sep 2018
Value US$57,860.55 | Price 3.51 | Shares 16,500
Planned buy 23 Aug 2018
Value US$282,320.00 | Price 2.82 | Shares 100,000
Planned buy 17 Aug 2018
Value US$300,002.40 | Price 2.63 | Shares 114,000
Planned sale 2 Jul 2018
Value US$13,932.00 | Price 2.79 | Shares 5,000
Planned sale 20 Apr 2018
Value US$20,550.00 | Price 4.11 | Shares 5,000
Planned sale 3 Nov 2017
Value US$390,000.00 | Price 3.90 | Shares 100,000
Planned sale 5 Jul 2017
Value US$13,427.00 | Price 2.69 | Shares 5,000
Planned sale 3 Jan 2017
Value US$12,027.50 | Price 2.41 | Shares 5,000
Planned sale 30 Aug 2016
Value US$21,214.12 | Price 4.00 | Shares 5,303
Sale 10 Jun 2015
Value US$153,214.22 | Price 3.68 | Shares 41,666
Sale 1 Apr 2015
Value US$37,518.00 | Price 3.75 | Shares 10,000
Sale 3 Sep 2014
Value US$51,200.00 | Price 2.56 | Shares 20,000
Sale 24 Feb 2014
Value US$74,238.00 | Price 3.71 | Shares 20,000
Sale 19 Nov 2013
Value US$404,343.34 | Price 2.64 | Shares 153,056
Sale 19 Nov 2013
Value US$875,931.06 | Price 2.64 | Shares 331,566
Buy 7 Jun 2013
Value US$28,095.31 | Price 3.47 | Shares 8,102
Buy 7 Jun 2013
Value US$85,298.48 | Price 3.47 | Shares 24,598
Sale 13 Sep 2012
Value US$43,283.72 | Price 10.43 | Shares 4,151
Sale 10 Sep 2012
Value US$184,927.34 | Price 10.52 | Shares 17,586
Sale 7 Sep 2012
Value US$248,560.10 | Price 10.67 | Shares 23,302
Sale 7 Sep 2012
Value US$359,960.06 | Price 10.55 | Shares 34,112
Sale 7 Aug 2012
Value US$3,187.50 | Price 10.63 | Shares 300
Sale 7 Aug 2012
Value US$6,372.00 | Price 10.62 | Shares 600
Sale 7 Aug 2012
Value US$1,061.00 | Price 10.61 | Shares 100
Sale 7 Aug 2012
Value US$7,420.00 | Price 10.60 | Shares 700
Sale 19 Jun 2012
Value US$871.00 | Price 8.71 | Shares 100
Sale 19 Jun 2012
Value US$84,390.00 | Price 8.70 | Shares 9,700
Sale 19 Jun 2012
Value US$872.49 | Price 8.72 | Shares 100
Sale 19 Jun 2012
Value US$875.00 | Price 8.75 | Shares 100
Buy 26 May 2011
Value US$2,411,392.00 | Price 8.00 | Shares 301,424
Buy 26 May 2011
Value US$1,834,016.00 | Price 8.00 | Shares 229,252
Buy 26 May 2011
Value US$582,400.00 | Price 8.00 | Shares 72,800
Buy 26 May 2011
Value US$372,192.00 | Price 8.00 | Shares 46,524
Sale 3 Nov 2010
Value US$27,859.50 | Price 7.55 | Shares 3,690
Sale 3 Nov 2010
Value US$19,667.75 | Price 7.55 | Shares 2,605
Sale 3 Nov 2010
Value US$6,795.00 | Price 7.55 | Shares 900
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-05-28 2026-05-26 PlS Planned sale
3.2
Ali-Jackson Kamil
Non-Executive Director
10,440 +32.2%
430.09
US$2,022,599 		10,440 +32.2% 430.09 US$2,022,599
2026-05-26 2026-05-26 PrS Proposed sale
3.2
Ali-Jackson Kamil

Director

Non-Executive Director
96,367
227.14
US$1,962,193 		96,367 227.14 US$1,962,193
2026-02-24 2026-02-20 S Sale
MOOS WALTER H
Non-Executive Director
10,019 -39.7%
120.94
US$4,664,552 		10,019 -39.7% 120.94 US$4,664,552
2026-02-20 2026-02-20 PrS Proposed sale
MOOS WALTER H

Director

Non-Executive Director
4,000
36.36
US$145,440 		4,000 36.36 US$145,440
2025-02-06 2025-02-05 S Sale
3.4
Santos David A

EVP, Chief Commercial Officer

Officer
1,796 -3.4%
21.93
US$39,379 		1,796 -3.4% 21.93 US$39,379
2025-02-06 2025-02-05 S Sale
3.1
Furey Raymond J.

EVP, GC, CCO & Corp Sec

Officer
1,339 -3.3%
21.93
US$29,359 		1,339 -3.3% 21.93 US$29,359
2025-02-06 2025-02-05 S Sale
4.1
RODRIGUEZ RAUL R

CEO, President

Executive Director
4,400 -1.8%
21.93
US$96,474 		4,400 -1.8% 21.93 US$96,474
2025-02-06 2025-02-05 S Sale
2.6
Schorno Dean L

EVP & Chief Financial Officer

Officer
1,734 -2.9%
21.93
US$38,020 		1,734 -2.9% 21.93 US$38,020
2025-02-05 2025-02-05 PrS Proposed sale
3.4
Santos David A

Officer

Officer
1,796
21.93
US$39,379 		1,796 21.93 US$39,379
2025-02-05 2025-02-05 PrS Proposed sale
2.6
Schorno Dean L

Officer

Officer
1,734
21.93
US$38,020 		1,734 21.93 US$38,020
2025-02-05 2025-02-05 PrS Proposed sale
3.1
Furey Raymond J.

Officer

Officer
1,339
21.93
US$29,359 		1,339 21.93 US$29,359
2025-02-05 2025-02-05 PrS Proposed sale
4.1
RODRIGUEZ RAUL R

Officer; Director

Executive Director
4,400
21.93
US$96,474 		4,400 21.93 US$96,474
2025-02-06 2025-02-04 S Sale
3.4
Santos David A

EVP, Chief Commercial Officer

Officer
2,125 -3.8%
20.92
US$44,457 		2,125 -3.8% 20.92 US$44,457
2025-02-06 2025-02-04 S Sale
3.1
Furey Raymond J.

EVP, GC, CCO & Corp Sec

Officer
1,448 -3.5%
20.92
US$30,294 		1,448 -3.5% 20.92 US$30,294
2025-02-06 2025-02-04 S Sale
4.1
RODRIGUEZ RAUL R

CEO, President

Executive Director
4,952 -2.0%
20.92
US$103,601 		4,952 -2.0% 20.92 US$103,601
2025-02-06 2025-02-04 S Sale
2.6
Schorno Dean L

EVP & Chief Financial Officer

Officer
2,036 -3.3%
20.92
US$42,595 		2,036 -3.3% 20.92 US$42,595
2025-02-04 2025-02-04 PrS Proposed sale
2.6
Schorno Dean L

Officer

Officer
2,036
20.92
US$42,596 		2,036 20.92 US$42,596
2025-02-04 2025-02-04 PrS Proposed sale
4.1
RODRIGUEZ RAUL R

Officer; Director

Executive Director
4,952
20.92
US$103,602 		4,952 20.92 US$103,602
2025-02-04 2025-02-04 PrS Proposed sale
3.1
Furey Raymond J.

Officer

Officer
1,448
20.92
US$30,294 		1,448 20.92 US$30,294
2025-02-04 2025-02-04 PrS Proposed sale
3.4
Santos David A

Officer

Officer
2,125
20.92
US$44,458 		2,125 20.92 US$44,458
2025-01-24 2025-01-24 PrS Proposed sale
Masuda Esteban

Officer

Officer
4,999
22.14
US$110,678 		4,999 22.14 US$110,678
2024-02-06 2024-02-05 S Sale
4.1
RODRIGUEZ RAUL R

CEO, President

Executive Director
30,545 -1.5%
1.14
US$34,821 		30,545 -1.5% 1.14 US$34,821
2024-02-06 2024-02-05 S Sale
2.6
Schorno Dean L

EVP & Chief Financial Officer

Officer
7,027 -1.7%
1.14
US$8,011 		7,027 -1.7% 1.14 US$8,011
2024-02-06 2024-02-05 S Sale
3.4
Santos David A

EVP, Chief Commercial Officer

Officer
8,918 -2.5%
1.14
US$10,167 		8,918 -2.5% 1.14 US$10,167
2024-02-06 2024-02-02 S Sale
4.1
RODRIGUEZ RAUL R

CEO, President

Executive Director
22,349 -1.1%
1.13
US$25,261 		22,349 -1.1% 1.13 US$25,261
2024-02-06 2024-02-02 S Sale
2.6
Schorno Dean L

EVP & Chief Financial Officer

Officer
5,601 -1.3%
1.13
US$6,327 		5,601 -1.3% 1.13 US$6,327
2024-02-06 2024-02-02 S Sale
3.4
Santos David A

EVP, Chief Commercial Officer

Officer
5,601 -1.5%
1.13
US$6,329 		5,601 -1.5% 1.13 US$6,329
2023-02-07 2023-02-06 S Sale
4.1
RODRIGUEZ RAUL R

CEO, President

Executive Director
20,340 -1.2%
1.75
US$35,595 		20,340 -1.2% 1.75 US$35,595
2023-02-06 2023-02-02 S Sale
2.6
Schorno Dean L

EVP & Chief Financial Officer

Officer
5,389 -2.7%
1.66
US$8,946 		5,389 -2.7% 1.66 US$8,946
2023-02-06 2023-02-02 S Sale
3.4
Santos David A

EVP, Chief Commercial Officer

Officer
5,388 -3.6%
1.66
US$8,945 		5,388 -3.6% 1.66 US$8,945
2023-02-06 2023-02-02 S Sale
3.1
Dummer Wolfgang

EVP & CMO

Officer
5,389 -6.9%
1.66
US$8,946 		5,389 -6.9% 1.66 US$8,946
2022-06-13 2022-06-09 B Purchase
4.1
RODRIGUEZ RAUL R

CEO, President

Executive Director
1,000,000 +255.2%
0.69
US$688,400 		1,000,000 +255.2% 0.69 US$688,400
2019-05-23 2019-05-22 B Purchase
2.6
Schorno Dean L

EVP &Chief Financial Officer

Officer
3,274 +7.0%
2.13
US$6,971 		3,274 +7.0% 2.13 US$6,971
2019-05-23 2019-05-22 B Purchase
2.6
Schorno Dean L

EVP &Chief Financial Officer

Officer
46,726 +inf%
2.13
US$99,573 		46,726 +inf% 2.13 US$99,573
2018-10-16 2018-10-12 PlS Planned sale Cabatuan Nelson

Principal Accounting Officer

Officer
10,000 -99.4%
3.12
US$31,200 		10,000 -99.4% 3.12 US$31,200
2018-09-19 2018-09-17 PlS Planned sale Duliege Anne-Marie

EVP & Chief Medical Officer

Officer
37,500 -100.0%
3.50
US$131,250 		37,500 -100.0% 3.50 US$131,250
2018-09-19 2018-09-17 PlS Planned sale Duliege Anne-Marie

EVP & Chief Medical Officer

Officer
115,500 -100.0%
3.50
US$404,250 		115,500 -100.0% 3.50 US$404,250
2018-09-12 2018-09-11 B Purchase Mayer Eldon C. III

EVP & Chief Commercial Officer

Officer
50,000 +30.3%
3.23
US$161,340 		50,000 +30.3% 3.23 US$161,340
2018-09-12 2018-09-10 B Purchase Mayer Eldon C. III

EVP & Chief Commercial Officer

Officer
50,000 +43.5%
3.28
US$164,210 		50,000 +43.5% 3.28 US$164,210
2018-09-06 2018-09-04 PlS Planned sale Duliege Anne-Marie

EVP & Chief Medical Officer

Officer
16,500 -100.0%
3.51
US$57,861 		16,500 -100.0% 3.51 US$57,861
2018-08-27 2018-08-23 PP Planned purchase Mayer Eldon C. III

EVP & Chief Commercial Officer

Officer
100,000 +666.7%
2.82
US$282,320 		100,000 +666.7% 2.82 US$282,320
2018-08-21 2018-08-17 PP Planned purchase RODRIGUEZ RAUL R

CEO, President

Executive Director
114,000 +191.5%
2.63
US$300,002 		114,000 +191.5% 2.63 US$300,002
2018-07-05 2018-07-02 PlS Planned sale Duliege Anne-Marie

EVP & Chief Medical Officer

Officer
5,000 -100.0%
2.79
US$13,932 		5,000 -100.0% 2.79 US$13,932
2018-04-24 2018-04-20 PlS Planned sale Duliege Anne-Marie

EVP & Chief Medical Officer
5,000 -100.0%
4.11
US$20,550 		5,000 -100.0% 4.11 US$20,550
2017-11-07 2017-11-03 PlS Planned sale Maynard Ryan D

EVP & CFO
100,000 -100.0%
3.90
US$390,000 		100,000 -100.0% 3.90 US$390,000
2017-07-07 2017-07-05 PlS Planned sale Duliege Anne-Marie

Chief Medical Officer

Officer
5,000 -100.0%
2.69
US$13,427 		5,000 -100.0% 2.69 US$13,427
2017-01-13 2017-01-03 PlS Planned sale Duliege Anne-Marie

Chief Medical Officer

Officer
5,000 -100.0%
2.41
US$12,028 		5,000 -100.0% 2.41 US$12,028
2016-09-01 2016-08-30 PlS Planned sale PAYAN DONALD G

EVP, Pres. Discovery&Research

Executive Director
5,303 -9.1%
4.00
US$21,214 		5,303 -9.1% 4.00 US$21,214
2015-06-12 2015-06-10 S Sale PAYAN DONALD G

EVP, Pres. Discovery&Research

Executive Director
41,666 -41.7%
3.68
US$153,214 		41,666 -41.7% 3.68 US$153,214
2015-04-03 2015-04-01 S Sale PAYAN DONALD G

EVP, Pres. Discovery&Research

Executive Director
10,000 -14.6%
3.75
US$37,518 		10,000 -14.6% 3.75 US$37,518
2014-09-05 2014-09-03 S Sale PAYAN DONALD G

EVP, Pres. Discovery&Research

Executive Director
20,000 -22.6%
2.56
US$51,200 		20,000 -22.6% 2.56 US$51,200
2014-02-26 2014-02-24 S Sale PAYAN DONALD G

EVP, Pres. Discovery&Research

Executive Director
20,000 -18.5%
3.71
US$74,238 		20,000 -18.5% 3.71 US$74,238
2013-11-20 2013-11-19 S Sale BVF PARTNERS L P/IL

See Explanation of Responses

Large shareholder
153,056 -19.1%
2.64
US$404,343 		153,056 -19.1% 2.64 US$404,343
2013-11-20 2013-11-19 S Sale BVF PARTNERS L P/IL

See Explanation of Responses

Large shareholder
331,566 -22.8%
2.64
US$875,931 		331,566 -22.8% 2.64 US$875,931
2013-06-11 2013-06-07 B Purchase BVF PARTNERS L P/IL

See Explanation of Responses

Large shareholder
8,102 +1.0%
3.47
US$28,095 		8,102 +1.0% 3.47 US$28,095
2013-06-11 2013-06-07 B Purchase BVF PARTNERS L P/IL

See Explanation of Responses

Large shareholder
24,598 +1.7%
3.47
US$85,298 		24,598 +1.7% 3.47 US$85,298
2012-09-14 2012-09-13 S Sale VANCE DOLLY

EVP Corp. Affairs, G.C., Sect.

Officer
4,151 -79.0%
10.43
US$43,284 		4,151 -79.0% 10.43 US$43,284
2012-09-11 2012-09-10 S Sale Maynard Ryan D

EVP & CFO

Officer
17,586 -100.0%
10.52
US$184,927 		17,586 -100.0% 10.52 US$184,927
2012-09-14 2012-09-07 S Sale Maynard Ryan D

EVP & CFO

Officer
23,302 -100.0%
10.67
US$248,560 		23,302 -100.0% 10.67 US$248,560
2012-09-11 2012-09-07 S Sale Maynard Ryan D

EVP & CFO

Officer
34,112 -100.0%
10.55
US$359,960 		34,112 -100.0% 10.55 US$359,960
2012-08-09 2012-08-07 S Sale Maynard Ryan D

EVP & CFO

Officer
300 -100.0%
10.63
US$3,188 		300 -100.0% 10.63 US$3,188
2012-08-09 2012-08-07 S Sale Maynard Ryan D

EVP & CFO

Officer
600 -66.7%
10.62
US$6,372 		600 -66.7% 10.62 US$6,372
2012-08-09 2012-08-07 S Sale Maynard Ryan D

EVP & CFO

Officer
100 -10.0%
10.61
US$1,061 		100 -10.0% 10.61 US$1,061
2012-08-09 2012-08-07 S Sale Maynard Ryan D

EVP & CFO

Officer
700 -41.2%
10.60
US$7,420 		700 -41.2% 10.60 US$7,420
2012-06-20 2012-06-19 S Sale PAYAN DONALD G

EVP, Pres. Discovery&Research

Executive Director
100 -0.1%
8.71
US$871 		100 -0.1% 8.71 US$871
2012-06-20 2012-06-19 S Sale PAYAN DONALD G

EVP, Pres. Discovery&Research

Executive Director
9,700 -8.2%
8.70
US$84,390 		9,700 -8.2% 8.70 US$84,390
2012-06-20 2012-06-19 S Sale PAYAN DONALD G

EVP, Pres. Discovery&Research

Executive Director
100 -0.1%
8.72
US$872 		100 -0.1% 8.72 US$872
2012-06-20 2012-06-19 S Sale PAYAN DONALD G

EVP, Pres. Discovery&Research

Executive Director
100 -0.1%
8.75
US$875 		100 -0.1% 8.75 US$875
2011-06-07 2011-05-26 B Purchase Flynn James E Large shareholder
301,424 +10.4%
8.00
US$2,411,392 		301,424 +10.4% 8.00 US$2,411,392
2011-06-07 2011-05-26 B Purchase Flynn James E Large shareholder
229,252 +11.2%
8.00
US$1,834,016 		229,252 +11.2% 8.00 US$1,834,016
2011-06-07 2011-05-26 B Purchase Flynn James E Large shareholder
72,800 +10.6%
8.00
US$582,400 		72,800 +10.6% 8.00 US$582,400
2011-06-07 2011-05-26 B Purchase Flynn James E Large shareholder
46,524 +11.0%
8.00
US$372,192 		46,524 +11.0% 8.00 US$372,192
2010-11-05 2010-11-03 S Sale Flynn James E Large shareholder
3,690 -0.1%
7.55
US$27,860 		3,690 -0.1% 7.55 US$27,860
2010-11-05 2010-11-03 S Sale Flynn James E Large shareholder
2,605 -0.1%
7.55
US$19,668 		2,605 -0.1% 7.55 US$19,668
2010-11-05 2010-11-03 S Sale Flynn James E Large shareholder
900 -0.1%
7.55
US$6,795 		900 -0.1% 7.55 US$6,795
Explore more

More insider trading research around Rigel Pharmaceuticals Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America